Media coverage
3
Media coverage
Title Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Media name/outlet Jotup Country/Territory United States Date 2/09/22 URL https://jotup.co/node/2046980 Persons Sameer Bansilal Title Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Media name/outlet BioSpace Country/Territory United States Date 1/09/22 URL https://www.biospace.com/article/releases/bayer-s-kerendia-finerenone-receives-updated-label-to-include-findings-from-phase-iii-figaro-dkd-cardiovascular-outcomes-study-in-patients-with-chronic-kidney-disease-and-type-2-diabetes/ Persons Sameer Bansilal Title Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Media name/outlet Yahoo! Finance Country/Territory United States Date 1/09/22 URL https://finance.yahoo.com/news/bayer-kerendia-finerenone-receives-updated-221500454.html Persons Sameer Bansilal